Skip to main content
. Author manuscript; available in PMC: 2013 Sep 3.
Published in final edited form as: Clin Cancer Res. 2012 Aug 21;18(20):5761–5772. doi: 10.1158/1078-0432.CCR-12-1182

Figure 5. The peptide encoded by mutated E255K elicits a memory response in association with disease control following nilotinib therapy.

Figure 5

A. ELIspot results from PBMC of Patient 2, collected at the time of complete response to nilotinib, demonstrating IFNγ secretion following exposure to both the E255K-B peptide and the E255K minigene. Results from duplicate wells are displayed. T cell responses were abrogated by blocking with the Class I MHC blocking antibody w6/32, confirming the class I restriction of these T cell responses. B. Graphical representation of ELISpot results. C. T cells reactive to the mutated peptide are polyfunctional, with secretion of IP-10, GM-CSF and TNF-α, measured by Luminex assay. Cytokine secretion results were depicted as fold over control cells (background cytokine secretion by T cells lines exposed to the antigen presenting cells (K562-A3) alone).